Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Alexandra Coomans de BrachèneAngela CastelaAnne Op de BeeckRaghavendra G MirmiraLorella MarselliPiero MarchettiCraig MasseWenyan MiaoSilvana LeitCarmella Evans-MolinaDecio L EizirikPublished in: Diabetes, obesity & metabolism (2020)
The two TYK2 inhibitors tested inhibit the IFNα signalling pathway in human beta cells, decreasing its pro-inflammatory and pro-apoptotic effects without sensitizing the cells to viral infection. The preclinical findings could pave the way for future clinical trials with TYK2 inhibitors for the prevention and treatment of type 1 diabetes.
Keyphrases
- induced apoptosis
- endothelial cells
- type diabetes
- clinical trial
- cell cycle arrest
- cell therapy
- cell death
- pluripotent stem cells
- endoplasmic reticulum stress
- immune response
- single cell
- cardiovascular disease
- anti inflammatory
- dendritic cells
- metabolic syndrome
- insulin resistance
- bone marrow
- mesenchymal stem cells
- randomized controlled trial
- combination therapy
- cell proliferation
- double blind